Skip to main content
Premium Trial:

Request an Annual Quote

HemoGenix to Help ImmuneRegen Validate Bioterror Drug Candidate

NEW YORK (GenomeWeb News) – The stem cell-based pharmaceutical company ImmuneRegen will use HemoGenix’ cell-based assay technology in its studies of a therapeutic candidate designed as a response to bioterrorism threats, ImmuneRegen said today.
The agreement calls for HemoGenix to use its instrument-based ATP bioluminescence technology to study the ability of a drug called Homspera to stimulate hematopoietic stem cell proliferation. The drug is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound that can improve pulmonary function and stimulate the human immune system, ImmuneRegen said.
HemoGenix’s technology offers a method for standardizing and validating the stem cell colony-forming cell differentiation assay, according to ImmuneRegen.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.